Polymorphisms of genes related to phase-I metabolic enzymes affecting the clinical efficacy and safety of clopidogrel treatment

@article{Alkattan2021PolymorphismsOG,
  title={Polymorphisms of genes related to phase-I metabolic enzymes affecting the clinical efficacy and safety of clopidogrel treatment},
  author={Abdullah N. Alkattan and Eman Alsalameen},
  journal={Expert Opinion on Drug Metabolism \& Toxicology},
  year={2021},
  volume={17},
  pages={685 - 695}
}
ABSTRACT Introduction: Clopidogrel is an antiplatelet medication described as a prodrug, which cannot exert the antiplatelet effect until being biotransformed to the active metabolite. It is commonly used to reduce the risk of blood coagulation in patients diagnosed with acute coronary syndrome, or ischemic stroke. Area covered: We reviewed published articles in PubMed and Google Scholar that focused on the mutations of CYP2C19, CYP3A4, CYP2C9, CYP2B6, and CYP1A2 genes related to clopidogrel… 
1 Citations
The role of CYP2C19 gene polymorphisms on antiplatelet activity of clopidogrel among Arabs: systematic review and meta-analysis
TLDR
It is revealed that Arabs carrying CYP2C19*2 and CYP19*3 alleles may not respond to clopidogrel and may put those patients at risk of recurrent CVEs and did not showed a significant role either in increase or decrease the antiplatelet efficacy of clopIDogrel.

References

SHOWING 1-10 OF 137 REFERENCES
Impact of CYP2C19 polymorphisms on the antiplatelet effect of clopidogrel in an actual clinical setting in Japan.
TLDR
CYP2C19 polymorphisms are frequent in Japanese, and the antiplatelet effect of clopidogrel is strongly affected by them in the real-world clinical setting.
Effects of CYP2C19 variant alleles on postclopidogrel platelet reactivity and clinical outcomes in an actual clinical setting in China
TLDR
Only CYP2C19*2 and *3, of the investigated polymorphisms, were associated with postclopidogrel platelet aggregation and the presence of high platelet reactivity, and only the two loss-of-function allele carriage was associated with clinical outcome in the first 6 months.
The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non‐ST acute coronary syndrome
TLDR
The aim of the present study was to evaluate the impact of these novel allelic variants of the CYP2C19 on platelet response to clopidogrel in patients suffering from non-ST elevation acute coronary syndrome (NSTE ACS).
Impact of CYP3A4*1G Allele on Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel
TLDR
In a multivariate analysis, which included age, body mass index, co-morbidities and coadministered drugs, CYP3A4*1G was not a predictor of values of H3 and H4 pharmacokinetic parameters and platelet aggregation.
Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation
TLDR
Besides CYP2C19*2, the variant allele CYP3A4*1B plays an important role in the response to clopidogrel in patients on dual antiplatelet therapy undergoing coronary stenting.
Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting
TLDR
The CYP2C19*2 loss-of-function polymorphism is associated with a more frequent occurrence of HPR, however, the part of the interindividual variability in on-treatment platelet reactivity explained by CYP1C20*2 genotype is modest.
Effect of the CYP2C19*2 and *3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention
TLDR
The CYP2C19 loss-of-function alleles had a gene dose effect on the pharmacodynamics and composite ischemic events of clopidogrel in the study population and neither the ABCB1 nor the PON1 genotype significantly influenced the antiplatelet effect and clinical outcomes of clobidog Rel in these patients.
Cytochrome p-450 polymorphisms and response to clopidogrel.
TLDR
Carriers of a reduced-function CYP2C19 allele had significantly lower levels of the active metabolite of clopidogrel, diminished platelet inhibition, and a higher rate of major adverse cardiovascular events, including stent thrombosis, than did noncarriers.
Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study.
TLDR
Loss-of-function polymorphism of the CYP2C19 gene, but not the ABCB1 C3435T and CYP3A5*3 andABCB1 3435C > T variants, affects the antiplatelet effect of triple anti-platelet therapy.
...
...